GeneGo, Inc. has announced that Elan Pharmaceuticals, Inc. licensed its flagship data analysis suite MetaCore™. The platform will be available to all scientists in research. MetaCore is designed for functional analysis of biological and chemistry data. Elan will use MetaCore in their neurology and autoimmune programs.
“We are very pleased that Elan chose GeneGo and we have had good interactions so far,” said Julie Bryant, GeneGo’s VP of Business development. “MetaCore has substantial knowledge content coverage in the areas of CNS and autoimmune diseases, which the Elan scientists can leverage in their innovative research.”